VNRX · Insider Trading
VolitionRx Limited
Every open-market purchase and sale reported by VNRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-23 | Ann-Louise Batchelor | Group Chief Marketing Officer | A | +12,000 | — |
| 2026-09-30 | Gaetan Michel | Chief Operating Officer | F | −608 | −$154 |
| 2026-09-30 | Gael Forterre | Chief Commercial Officer | F | −284 | −$72 |
| 2026-03-19 | Nicholas Plummer | GC - Volition Diagnostics | F | −7,003 | −$1.33K |
| 2026-03-19 | Rodney Gerard Rootsaert | Secretary | F | −3,948 | −$750 |
| 2026-03-19 | Gael Forterre | Chief Commercial Officer | F | −5,251 | −$998 |
| 2026-03-19 | Jacob Vincent Micallef | Chief Scientific Officer | F | −5,310 | −$1.01K |
| 2026-03-03 | Nicholas Plummer | GC - Volition Diagnostics | F | −5,867 | −$1.25K |
| 2026-03-03 | Gael Forterre | Chief Commercial Officer | F | −2,283 | −$486 |
| 2026-03-03 | Rodney Gerard Rootsaert | Secretary | F | −3,321 | −$707 |
| 2026-02-27 | Terig Hughes | Chief Financial Officer | A | +202,000 | — |
| 2026-02-27 | Gael Forterre | Chief Commercial Officer | A | +149,000 | — |
| 2026-02-27 | Cameron John Reynolds | President and CEO | A | +486,000 | — |
| 2026-02-27 | Nicholas Plummer | GC - Volition Diagnostics | A | +187,000 | — |
| 2026-02-27 | Ethel Rubin | Director | A | +178,000 | — |
| 2026-02-27 | Ann-Louise Batchelor | Group Chief Marketing Officer | A | +142,000 | — |
| 2026-02-27 | Jasmine Kway | CEO - Singapore Volition | A | +173,000 | — |
| 2026-02-27 | Rodney Gerard Rootsaert | Secretary | A | +119,000 | — |
| 2026-02-27 | Kim Nguyen | Director | A | +178,000 | — |
| 2026-02-27 | Jacob Vincent Micallef | Chief Scientific Officer | A | +149,000 | — |
| 2026-02-27 | Guy Archibald Innes | Director | A | +178,000 | — |
| 2026-02-03 | Nicholas Plummer | GC - Volition Diagnostics | F | −5,647 | −$1.61K |
| 2026-02-03 | Gael Forterre | Chief Commercial Officer | F | −2,010 | −$573 |
| 2026-02-03 | Rodney Gerard Rootsaert | Secretary | F | −3,196 | −$911 |
| 2026-01-23 | Terig Hughes | Chief Financial Officer | A | +49,200 | — |
| 2026-01-23 | Mickie Henshall | Director | A | +12,000 | — |
| 2026-01-23 | Nicholas Plummer | GC - Volition Diagnostics | A | +44,700 | — |
| 2026-01-23 | Ann-Louise Batchelor | Group Chief Marketing Officer | A | +33,900 | — |
| 2026-01-23 | Timothy I Still | Director | A | +90,000 | — |
| 2026-01-23 | Phillip Barnes | Director | A | +12,000 | — |
| 2026-01-23 | Jacob Vincent Micallef | Chief Scientific Officer | A | +35,400 | — |
| 2026-01-23 | Cameron John Reynolds | President and CEO | A | +74,700 | — |
| 2026-01-23 | Alan Colman | Director | A | +12,000 | — |
| 2026-01-23 | Rodney Gerard Rootsaert | Secretary | A | +28,200 | — |
| 2026-01-23 | Jasmine Kway | CEO - Singapore Volition | A | +42,000 | — |
| 2026-01-23 | Salvatore Thomas Butera | CEO - Volition Veterinary | A | +53,400 | — |
| 2026-01-23 | Gael Forterre | Chief Commercial Officer | A | +38,100 | — |
| 2026-01-23 | Guy Archibald Innes | Director | A | +12,000 | — |
| 2026-01-23 | Kim Nguyen | Director | A | +12,000 | — |
| 2026-01-23 | Ethel Rubin | Director | A | +12,000 | — |
| 2025-11-17 | Cameron John Reynolds | President and CEO | Buy | +20,000 | +$7.00K |
| 2025-11-04 | Andrew Retter | Chief Medical Officer | F | −4,588 | −$1.99K |
| 2025-11-04 | Nicholas Plummer | GC - Volition Diagnostics | F | −5,647 | −$2.45K |
| 2025-11-04 | Salvatore Thomas Butera | CEO - Volition Veterinary | F | −4,648 | −$2.02K |
| 2025-11-04 | Rodney Gerard Rootsaert | Secretary | F | −3,197 | −$1.39K |
| 2025-11-04 | Gael Forterre | Chief Commercial Officer | F | −1,753 | −$761 |
| 2025-10-15 | Timothy I Still | Director | Buy | +48,076 | +$24.52K |
| 2025-10-15 | Cameron John Reynolds | President and CEO | Buy | +110,000 | +$56.10K |
| 2025-10-15 | Guy Archibald Innes | Director | Buy | +96,153 | +$49.04K |
| 2025-10-07 | Nicholas Plummer | GC - Volition Diagnostics | F | −8,146 | −$5.28K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Cameron John Reynolds | President and CEO | 206,163 | $41.23K |
| Guy Archibald Innes | Director | 132,648 | $26.53K |
| Timothy I Still | Director | 81,273 | $16.25K |
| Rodney Gerard Rootsaert | Secretary | 64,086 | $12.82K |
| Terig Hughes | Chief Financial Officer | 34,248 | $6.85K |
| Jacob Vincent Micallef | Chief Scientific Officer | 31,359 | $6.27K |
| Ann-Louise Batchelor | Group Chief Marketing Officer | 29,257 | $5.85K |
| Jasmine Kway | CEO - Singapore Volition | 21,451 | $4.29K |
| Nicholas Plummer | GC - Volition Diagnostics | 20,363 | $4.07K |
| Kim Nguyen | Director | 16,819 | $3.36K |
| Gael Forterre | Chief Commercial Officer | 16,534 | $3.31K |
| Alan Colman | Director | 12,868 | $2.57K |
| Ethel Rubin | Director | 12,647 | $2.53K |
| Gaetan Michel | Chief Operating Officer | 12,232 | $2.45K |
| Andrew Retter | Chief Medical Officer | 7,328 | $1.47K |
| Salvatore Thomas Butera | CEO - Volition Veterinary | 4,968 | $994 |
| Phillip Barnes | Director | 3,368 | $674 |
| Mickie Henshall | Director | 2,210 | $442 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VNRX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.